- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02335671
Evaluating Mass Spectrometry And Intraoperative MRI In The Advanced Multimodality Image Guided Operating Suite (Amigo) In Breast-Conserving Therapy
Study Overview
Status
Detailed Description
This research study is a Phase II clinical trial investigating the use of intra-operative MRI and MS in breast cancer surgery. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied.
Prior research has shown that intraoperative MRI and MS are two types of tests that are feasible to use during cancer surgery and may be able to guide therapy. In this study, we are evaluating the accuracy of intra-operative MRI and MS in determining whether or not all cancer tissue was removed during breast surgery.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Thanh Barbie, MD
- Phone Number: (617) 632-3209
- Email: tbarbie@bwh.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, United States, 02215
- Brigham and Women's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must be female
- Participants must have a pre-operative standard mammogram with or without ultrasound. These may be performed at outside institutions.
- Participants must have biopsy confirmed and clinical stage 1 or stage 2 breast carcinoma. If biopsy was done at an outside hospital, pathology will be reviewed at BWH/DFCI.
- Participants must be candidates for definitive local therapy with breast conserving therapy (this takes into account tumor to breast size ratio appropriate for BCS, and the ability to undergo standard radiation therapy post-operatively).
- Patient must meet standard MRI guidelines and be able and willing to undergo MRI
- Age ≥18 years and < 75.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Participants with a known BRCA 1 or 2 mutation.
- Participants with known Li-Fraumeni or Cowden's Disease.
- Participants with prior mantle radiation.
- Participants with locally advanced breast cancer such as inflammatory breast cancer or cancer grossly involving skin.
- Participants who are pregnant.
- Participants who enroll in a preoperative therapy trial or who have been treated with neoadjuvant chemotherapy.
- Participants with known active collagen vascular disease.
- Participants with prior history of ipsilateral breast carcinoma.
- Patients who have biopsy confirmed multi-centric disease.
- Participants who have documented contra-indications for contrast-enhanced MRI, including but not limited to renal failure.
- Participants who exceed the weight limit for the surgical table at AMIGO, 350 lbs or who will not fit into the 70 cm diameter bore of the MRI scanner at AMIGO or the 60 cm diameter bore of the pre-procedure imaging MRI scanner.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intra-operative Magnetic Resonance Imaging (MRI)
|
Analysis of Tissue Sample
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the accuracy of MRI in detecting tumor boundaries
Time Frame: 2 Years
|
2 Years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the operating characteristics (sensitivity, specificity, negative predictive value and positive predictive value) of MRI in detecting tumor boundaries as confirmed with pathologic results
Time Frame: 2 Years
|
2 Years
|
To evaluate the correlation of intraoperative mass spectrometry results to tumor boundaries as confirmed with pathologic results.
Time Frame: 2 Years
|
2 Years
|
To develop novel image processing algorithms to detect remnant tumor from intraoperative DCE-MRI in presence of tissue edema and reduced perfusion
Time Frame: 2 Years
|
2 Years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Thanh Barbie, MD, Dana-Farber Cancer Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14-476
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Early Stage Breast Cancer
-
Jonsson Comprehensive Cancer CenterDaiichi Sankyo Co., Ltd.; Translational Research in Oncology-U.SRecruitingInvasive Breast Cancer | Stage II Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Hormone Receptor Positive Breast Carcinoma | Early-stage Breast Cancer | Stage III Breast CancerUnited States
-
Tanvex BioPharma USA, Inc.CompletedBreast Cancer | Breast Neoplasms | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Early-stage Breast CancerBelarus, Chile, Georgia, Hungary, India, Mexico, Peru, Philippines, Russian Federation, Ukraine
-
Stanford UniversityTerminatedBreast Cancer | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer Metastatic Breast CancerUnited States
-
Stanford UniversityNational Institutes of Health (NIH); University of California; Breast Cancer... and other collaboratorsActive, not recruitingBreast Cancer | Breast Cancer Non-invasive Breast Cancer | Breast Cancer Early Stage Breast Cancer (Stage 1-3)United States
-
Shandong Cancer Hospital and InstituteRecruitingEarly-stage Breast Cancer | Breast Conserving SurgeryChina
-
University of Wisconsin, MadisonRecruitingEarly-stage Breast CancerUnited States
-
MedStar Franklin Square Medical CenterMedstar Health Research InstituteActive, not recruitingEarly Stage Breast CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Active, not recruitingStage 0 Breast Cancer | Cancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Early-Stage Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Dana-Farber Cancer InstituteThe Comprehensive and Integrative Medicine Institute of South KoreaRecruitingBreast Cancer Stage I | Breast Cancer Stage II | Acupuncture | Breast Cancer Stage III | Chemotherapy-induced Peripheral Neuropathy | Early-stage Breast CancerUnited States
-
Rigshospitalet, DenmarkNot yet recruitingEarly-stage Breast Cancer
Clinical Trials on Intra-operative Magnetic Resonance Imaging (MRI)
-
Vilnius UniversityActive, not recruitingAortic Stenosis, CalcificDenmark, Lithuania
-
Insel Gruppe AG, University Hospital BernRecruiting
-
Centre Hospitalier Universitaire, AmiensCompletedHepatic Flow ChangesFrance
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingProstate CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBrain NeoplasmUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingProstate Adenocarcinoma | Prostate CarcinomaUnited States
-
University of MichiganPhilips Healthcare; General ElectricCompleted
-
American College of RadiologyPennsylvania Department of HealthCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Recruiting
-
University of CincinnatiActive, not recruitingProstate CancerUnited States